12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Pharming, Shanghai Institute of Pharmaceutical Industry deal

Pharming and the institute partnered to develop, manufacture and commercialize recombinant human proteins using Pharming's GMP-compliant platform. Pharming will transfer its platform and manufacturing know-how to the institute, and joint global development for new products will take place at the institute's facility in Shanghai. The partners will initially work to develop a recombinant human Factor VIII product to treat hemophilia A. The institute will fund preclinical...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >